Quarterly report pursuant to Section 13 or 15(d)

Noncontrolling Interest (Tables)

v3.22.2.2
Noncontrolling Interest (Tables)
6 Months Ended
Jun. 30, 2022
Noncontrolling Interest [Abstract]  
Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

 

    June 30, 2022     December 31, 2021  
NCI – equity (deficit) – beginning of period   $ 17,752     $ (2,369 )
Investment in Veris Health Inc.           6  
Net loss attributable to NCI - Lucid Diagnostics Inc.     (5,711 )     (5,779 )
Net loss attributable to NCI – Solys Diagnostics Inc.     (6 )      
Net loss attributable to NCI – Veris Health Inc.     (620 )      
Impact of subsidiary equity transactions     229       16,760  
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     688        
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     7,091       9,134  
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan     3        
NCI – equity (deficit) – end of period   $ 19,426     $ 17,752